Elon Musk Podcast Sam Altman’s Merge Labs Explores Gene Therapy for Brain-AI Interface
8 snips
Aug 17, 2025 Sam Altman discusses his new venture, Merge Labs, which is pioneering a gene therapy approach to brain-computer interfaces. They aim to modify brain cells to respond to ultrasound, creating a less invasive method for connecting thoughts with AI. The company is raising substantial funds and competing directly with established players like Neuralink, but with a unique focus on high-bandwidth communication through sonogenetics and ultrasound technology. This innovative strategy could revolutionize how we interact with artificial intelligence.
AI Snips
Chapters
Transcript
Episode notes
Gene Therapy Meets Ultrasound
- Merge Labs plans to genetically alter neurons so they respond to ultrasound for brain-AI communication.
- This combines sonogenetics with implants to aim for thought-to-AI interaction without typing or speaking.
A Different Path From Neuralink
- Merge's sonogenetics route contrasts with Neuralink's electrode-based implants and aims for acoustic stimulation of engineered cells.
- This could avoid electrode issues like scar tissue and long-term signal decay if safety hurdles are cleared.
Skull-Embedded Ultrasound Hardware
- Merge is exploring embedding ultrasound hardware into the skull to interact with modified brain tissue in real time.
- The goal is less invasive detection and control without deep probes or wired electrodes.